loader image
Friday, October 24, 2025
75.3 F
McAllen
- Advertisement -

Two Coronavirus Vaccines Enter Final Stages of Clinical Trials

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

As communities across the country consider whether to reopen schools and offices this fall, leaders are pinning their hopes to a COVID-19 vaccine that will soon be available.

The Chamber’s latest interactive map breaks down where clinical trials for COVID-19 vaccines and therapeutics are happening in the United States. There are currently 25 vaccines in the clinical stage of development, and just yesterday two entered the final stages.

Moderna began a Phase 3, 30,000-person trial for its leading vaccine candidate, developed in partnership with the National Institute of Allergy and Infectious Diseases. A day ahead of the beginning of the trial, the U.S. government threw additional support behind Moderna’s vaccine, committing an additional $472 million to the Phase 3 trial.

- Advertisement -

Late Monday afternoon, Pfizer and BioNTech announced the start of a global Phase 2/3 30,000-person safety and efficacy clinical trial for their leading mRNA vaccine candidate. If the vaccine candidate proves effective, the companies plan to seek regulatory approval as early as October 2020, with the goal of providing up to 100 million doses globally by the end of the year.

The story of these three innovative companies sheds light on the risk required to invest in innovative, life-saving treatments. To date, there has not yet been a successful mRNA vaccine developed. Should either the Moderna or Pfizer and BioNTech vaccine candidates prove successful, it would be an unprecedented breakthrough.

As these companies work at warp speed alongside other biopharmaceutical companies with vaccines in clinical development, the scientific community recognizes that an effective vaccine cannot come quickly enough. 

With our brightest scientific minds, the most innovative companies, and the nation’s leading universities on the task, the Chamber is confident that we will have an effective vaccine to help lead the global community out of this crisis soon. 

- Advertisement -

–Jonathan Weinberger, Executive Vice President, U.S. Chamber Global Innovation Policy Center

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

University of Houston & DHR Health Multi-Million Dollar Medical Research & Education Center in the RGV

The University of Houston and DHR Health Hospital System today announced an agreement to establish The University of Houston Tilman J. Fertitta Family College of Medicine and DHR Health Medical Research and Education Center in the Rio Grande Valley.

Persistence in Adversity Foundation Launches 6th Annual Blanket Drive

Dr. Esmeralda Adame, founder of the Persistence in Adversity Foundation, is once again rallying the Rio Grande Valley community for a cause that brings both warmth and compassion. The foundation has launched its 6th Annual Blanket Drive, aiming to collect 1,000 new blankets for families, the elderly, and those in need across the region.

“I Was Diagnosed with Lung Cancer and Cured in Just 14 Days,” said Juan Camacho

In a landmark moment for healthcare in the Rio Grande Valley, DHR Health has achieved dual national recognition as both a Center of Excellence in Lung Cancer Screening and a Center of Excellence in Lung Cancer Care by GO2 for Lung Cancer, a leading organization dedicated to improving outcomes and survival rates for patients facing lung cancer.

2025 DHR Health Fashion Show & Gala Honoring Heroic Patients

The Edinburg Conference Center at Renaissance was filled with emotion, gratitude, and hope on Wednesday, October 15, 2025, as DHR Health hosted its 2025 Fashion Show & Gala Honoring Heroic Patients. The annual event celebrated breast cancer survivors and highlighted the importance of breast reconstruction awareness, education, and innovation in women’s health care.
- Advertisement -
×